MAPK13 and neoplasm: Together, these findings indicate that MAPK13 induction by rapamycin limits the tumor-suppressive effects of rapamycin, and the combinatory treatment of rapamycin with MAPK13 inhibitor can be more effective in impairing tumor growth compared with the rapamycin monotherapy (Fig. 4I).